olysio
janssen-cilag (new zealand) ltd - simeprevir sodium 154.4mg equivalent to simeprevir 150.0 mg - capsule - 150 mg - active: simeprevir sodium 154.4mg equivalent to simeprevir 150.0 mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin lactose monohydrate magnesium stearate opacode black s-1-277002 sodium laurilsulfate - olysio is indicated for the treatment of chronic hepatitis c (chc) genotype 1 or genotype 4 infection, in combination with other medicinal products for the treatment of chc infection.
olysio 150mg capsules
janssen-cilag ltd - simeprevir sodium - capsule - 150mg
galexos capsule
janssen inc - simeprevir (simeprevir sodium) - capsule - 150mg - simeprevir (simeprevir sodium) 150mg - hcv protease inhibitors
olysio simeprevir capsule
janssen products lp - simeprevir (unii: 9ws5rd66hz) (simeprevir - unii:9ws5rd66hz) - simeprevir 150 mg
olysio
janssen-cilag international nv - simeprevir - hepatitis c, chronic - antivirals for systemic use - olysio is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adult patients.for hepatitis c virus (hcv) genotype specific activity.
rosuvastatin galenicum 10mg film-coated tablets
galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - rosuvastatin - film-coated tablet - rosuvastatin 10 mg - lipid modifying agents
rosuvastatin galenicum 20mg film-coated tablets
galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - rosuvastatin - film-coated tablet - rosuvastatin 20 mg - lipid modifying agents
rosuvastatin galenicum 40mg film-coated tablets
galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - rosuvastatin - film-coated tablet - rosuvastatin 40 mg - lipid modifying agents
rosuvastatin 40mg tablets
zentiva pharma uk ltd - rosuvastatin calcium - oral tablet - 40mg
rosuvastatin 10mg tablets
zentiva pharma uk ltd - rosuvastatin calcium - oral tablet - 10mg